Biofusion Launches Absynth Biologics to Focus on New Treatments for MRSA infection

02-Feb-2007

Biofusion plc, the university IP commercialisation company, announced the launch of a new portfolio company, Absynth Biologics Ltd, which will develop vaccines and antibodies to treat infections caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).

Biofusion has agreed to invest up to £325,000 in the Company to enable it to produce lead vaccine and therapeutic antibody candidates to begin the clinical trial process. Absynth's unique patented technology has been developed at the University of Sheffield and will be used to develop an MSRA vaccine and antibodies to treat significant MRSA related infections as well as other applications.

In accordance with all its new spin-out companies, Biofusion owns 100% of the university's share in Absynth, resulting in a 60% shareholding on incorporation.

The launch of Absynth brings the total number of companies in the Biofusion portfolio to 22, 15 based on research from the University of Sheffield and seven based on research from Cardiff University.

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous